Newron Pharmaceuticals S.p.A.
Biopharmaceutical company developing therapies for nervous system disorders and pain.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Manufacturing
Description
Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-08 07:00 |
Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinica…
|
English | 19.2 KB | ||
| 2025-12-08 01:00 |
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III glob…
|
English | 17.5 KB | ||
| 2025-12-08 01:00 |
EQS-News: Newron gibt US-Start der globalen klinischen Phase-III-Studie ENIGMA-…
|
German | 20.3 KB | ||
| 2025-12-03 13:54 |
Newron Pharmaceuticals S.p.A.: Luca Benatti, sell
|
English | 6.0 KB | ||
| 2025-11-27 15:10 |
Newron Pharmaceuticals S.p.A.: Luca Benatti, sell
|
English | 6.3 KB | ||
| 2025-10-02 07:00 |
Newron to present new analyses from and updates on its clinical program evaluat…
|
English | 18.0 KB | ||
| 2025-10-02 02:00 |
EQS-News: Newron to present new analyses from and updates on its clinical progr…
|
English | 16.4 KB | ||
| 2025-10-02 02:00 |
EQS-News: Newron präsentiert neue Analysen und Updates zu seinem klinischen Pro…
|
German | 17.3 KB | ||
| 2025-09-16 07:00 |
Newron veroffentlicht die Ergebnisse des ersten Halbjahres 2025 und gibt ein Up…
|
German | 16.9 KB | ||
| 2025-09-16 02:00 |
EQS-Adhoc: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und …
|
German | 15.2 KB | ||
| 2025-09-16 02:00 |
EQS-News: Newron presents H1 2025 results and provides business update
|
English | 24.2 KB | ||
| 2025-09-16 02:00 |
EQS-News: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2025 und g…
|
German | 28.2 KB | ||
| 2025-09-05 07:00 |
Newron to present data and updates on its clinical program evaluating evenamide…
|
English | 19.3 KB | ||
| 2025-09-05 02:00 |
EQS-News: Newron to present data and updates on its clinical program evaluating…
|
English | 17.6 KB | ||
| 2025-09-05 02:00 |
EQS-News: Newron präsentiert Daten und Updates zu seinem klinischen Programm zu…
|
German | 14.3 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Newron Pharmaceuticals S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
